Vernakalant
Phase 3Small molecule
Vernakalant is one of 5 small molecule programs targeting Post-Operative Atrial Fibrillation. It is currently in Phase 3.
1
Indications
13
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Post-Operative Atrial Fibrillation
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Vernakalant
AAdvanz Pharma
Phase 3
Epsom Salt
FFresenius Kabi USA, LLC
Preclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atrial Fibrillation8 trials
Show 5 more trials
Atrial Flutter1 trial
Intravenous1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vernakalant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAdvanz Pharma